Ruixin Medical Listed in 2025 China Medical Device AI-Assisted Diagnosis Innovation Index Ahead of IPO

Recently, the National Innovation Center for High-Performance Medical Devices officially released the "2025 Annual Medical Device Industry Innovation Ecosystem Insight Assessment" results.RaysightMed Successfully Included in "2025 Medical Device Industry AI-Assisted Diagnosis Field Innovation Index" as a Prominent Innovative Force in This Niche Sector

This evaluation was initiated and organized by the National Innovation Center for High-Performance Medical Devices, aiming to promote the high-quality development of the high-performance medical device industry and accelerate the cultivation of new productive forces in China's medical equipment sector. Since its launch in 2022, the evaluation system has achieved a comprehensive upgrade from "single selection" to "building an industrial closed loop," always resonating with the industry and continuously empowering the evolution of the industrial ecosystem.

The 2025 annual evaluation focuses on the full-chain closed loop of technology R&D, achievement transformation, and market application. Through multiple rounds of rigorous review, it selects enterprises, institutions, and products that represent the new force in China's medical device industry.RaysightMed's innovative practices and achievements in AI-assisted diagnosis have received high recognition from review experts and industry institutions, demonstrating the vitality and development potential of China's medical device industry in intelligent transformation.

As a leading enterprise in the integration of AI and robotic-assisted precision cardiac intervention diagnosis and treatment, RaysightMed has been committed to deeply integrating artificial intelligence technology with clinical medicine, creating an integrated intelligent platform covering cardiac screening, diagnosis, surgical planning, and prognosis management. The recognition as an innovator in the AI-assisted diagnosis field not only affirms RaysightMed's technical strength and innovation capabilities but also highlights its active role in promoting the implementation of AI in healthcare and participating in building an innovative industry ecosystem.

In the future, RaysightMed will continue to rely on the guidance of national-level innovation platforms, strengthen scientific research and clinical transformation, collaborate with industrial chain partners, jointly promote the deep integration and application expansion of AI technology in the medical field, actively participate in the construction of the medical device industry's innovation ecosystem, contribute to the high-quality development of the industry, and enhance the global competitiveness of China's high-end medical equipment.

RaysightMed CEO Zheng Lingxiao Interprets the New Paradigm of "Macro + Micro" AI Coronary Diagnosis and Treatment at Jinan University

University-Enterprise Collaboration | RaysightMed Partners with the First Affiliated Hospital of Jinan University to Jointly Cultivate Interdisciplinary Talent in Intelligent Healthcare

Comprehensive and Precise, Evidence-Based Decision-Making | Zhangzhou People's Hospital Utilizes RaysightMed AngioQFA to Successfully Diagnose and Treat Occult Coronary Artery Disease